Leap Ther­a­peu­tics jumps in­to grow­ing Claudin18.2 field by buy­ing Flame Bio­sciences

Flame Bio­sciences gave up on its IL-1ß in­hibitor last fall af­ter No­var­tis’ as­set in the class failed mul­ti­ple stud­ies. To save it­self, the biotech is sell­ing to Leap Ther­a­peu­tics.

Not in the fore­ground of the pic­ture? The IL-1ß in­hibitor, known as FL-101. In­stead, Leap’s buy­out fo­cus­es on an­ti-Claudin18.2 an­ti­body FL-301 and two pre­clin­i­cal an­ti­bod­ies, in­clud­ing an an­ti-Claudin18.2/CD137 bis­pe­cif­ic and an­ti-GDF15 mon­o­clon­al.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN